Senior medical analyst Dr. Marc Siegel discusses advancements in artificial intelligence aimed at predicting an individual's future risk of breast cancer and the increased health risks from cannabis as users age. The U.S. Food and Drug Administration (FDA) has approved the first artificial intelligence (AI) tool to predict breast cancer risk. The authorization was confirmed by digital health tech company Clairity, the developer of Clairity Breast – a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram. In a press release, Clairity shared its plans to launch the AI platform across health systems through 2025. Most risk assessment models for breast cancer rely heavily on age and family history, according to Clairity.